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Prostaglandin-mediated suppression of in vitro growth of
erythroid progenitor cells
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The First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan
Prostaglandin-mediated suppression of in vitro growth of erythroid
progenitor cells. In vitro hematopoiesis was evaluated in 37 patients
with chronic renal failure (CRF) who developed moderate to severe
anemia in order to clarify the relationship between the growth of
erythroid progenitor cells and CRF-associated anemia. Bone marrow
cells from these patients were cultured in the presence of recombinant
erythropoietin. Both early and late erythroid progenitor cells (BFU-E
and CFU-E) were significantly suppressed in patients with CRF com-
pared to those in normal controls, while myeloid progenitor cells
(GM-CFC) remained normal. Suppression of CFU-E was shown to be
mediated by prostaglandin(s) secreted from bone marrow adherent
cells. Furthermore, the suppression of CFU-E was inversely correlated
with concentrations of uremic serum or parathyroid hormone added to
the assay system. These observations suggest a possibility that late
erythroid progenitor cells may be preferentially suppressed by the
network consisting of parathyroid hormone, bone marrow adherent
cells and prostaglandin(s).
Patients with chronic renal failure (CRF) undergoing hemo-
dialysis suffer from severe anemia requiring frequent red cell
transfusions [1]. One mechanism involved in the development
of CRF-associated anemia is an inappropriately low level of
erythropoietin (Epo) for the degree of anemia [2, 31. Recently,
biologically-active recombinant Epo (rEpo) has been available
for clinical use and its effectiveness has been reported [4—6].
However, mechanisms of CRF-associated anemia are too com-
plicated to be explained by the inappropriate production of Epo
alone. Other contributing factors include shortened red cell
survival [7], inhibitors or toxic metabolites which inhibit eryth-
ropoiesis [8, 91, iron and folate deficiency [10, 11], and alminum
toxicity [12]. Furthermore, parathyroid hormone (PTH), which
is frequently elevated as a result of secondary hyperparathy-
roidism in patients with CRF, may suppress erythropoiesis
[13—16]. Although humoral factors affecting erythropoiesis in
uremic sera have been extensively investigated, their precise
roles have not been demonstrated [17, 18]. In the present study,
we investigated erythroid colony formation in the presence of
rEpo by bone marrow cells from patients with CRF-associated
anemia, and found that in vitro growth of the early and late
erythroid progenitor cells (BFU-E and CFU-E) were sup-
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pressed though they could respond to rEpo. The suppression of
CFU-E was mediated by prostaglandin (PG) secreted by adher-
ent cells in the bone marrow, which have been known to
regulate hematopoiesis by producing some colony stimulating
factors or PGs [19—24]. Furthermore, PTH in uremic sera was
proved to be actively involved in the secretion of PG by
adherent cells.
Methods
Subjects
Thirty-seven patients with anemia associated with CRF, who
were undergoing hemodialysis regularly, were studied. Clinical
data including hemoglobin concentrations and serum levels of
creatinine and blood urea nitrogen were collected in all of the
patients. Nephrectomized patients were excluded from this
study. Informed consent was obtained prior to study entry.
Sera were obtained just prior to routine hemodialysis and stored
at —20°C.
Cell preparation
Bone marrow cells were obtained in a heparinized syringe by
sternal bone marrow aspiration from eight healthy volunteers
and from the patients just prior to routine hemodialysis. Light-
density bone marrow mononuclear cells (MNC), separated by
Ficoll-Hypaque gradient centrifugation, were washed three
times in Alpha Minimal Essential Medium (GIBCO, Grand
Island, New York, USA) and suspended in Iscove's Modified
Dulbecco's Medium (IMDM, GIBCO) supplemented with 10%
fetal calf serum (FCS, GIBCO).
Clonal assays for CFU-E
Assays for CFU-E were performed as described previously
[251. In brief, bone marrow MNC at a final concentration of 2 x
l0 cells/mi were plated in 35 mm plastic Petri dishes (Lux 5221,
Miles Scientific, Napervilie, Illinois, USA) in I ml of IMDM
containing 0.88% methylcellulose, 30% FCS, 5 X 10 M
2-mercaptoethanol (2-ME; Sigma Chemical Company, St.
Louis, Missouri, USA) and various concentrations of rEpo.
rEpo was purified from the supernatant of mammalian cell
BHK-21 transfected with a plasmid containing a cloned human
genomic Epo gene (SNB 5001; Snow Brand Milk Products Co.,
Ltd., Tokyo, Japan) [26]. Dishes were incubated at 37°C in a
humidified atmosphere with 5% CO2 in air. After seven days of
incubation, clusters of 8 to 64 hemoglobinized cells were
counted as CFU-E colonies using an inverted microscope.
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Clonal assays for BFU-E and GM-CFC
Assays for BFU-E (burst-forming unit-erythroid) and GM-
CFC (granulocyte-macrophage colony-forming cells) were per-
formed as described previously [27]. In brief, bone marrow
MNC at a final concentration of 2 x iO cells were plated in 35
mm plastic Petri dishes (Lux 5221) in I ml of IMDM containing
0.88% methylcellulose, 30% pooled plasma from patients with
aplastic anemia, 5% PHA-activated lymphocyte conditioned
medium, 5 x l0— M 2-ME and 1,000 mU of rEpo. After 14 days
of incubation, colonies consisting of three or more subcolonies
or large single accumulations of hemoglobinized cells were
counted as BFU-E colonies, while those of 20 or more granu-
locytes or monocytes as GM-CFC colonies.
Adherent cell depletion
Bone marrow adherent cells were depleted according to the
method of Messner, Till and McCulloch as described [281. In
brief, 2 x iO bone marrow MNC were plated in a 100 mm glass
dish containing 10 ml of IMDM supplemented with 10% FCS,
and were incubated at 37°C for two hours in a humidified
incubator. After the incubation, non-adherent cells were har-
vested, diluted in a methylcellulose mixture to the starting
volume and plated for CFU-E, BFU-E and GM-CFC assays.
Since the cell concentration was not readjusted before plating,
a 1 ml aliquot containing 2 x 1O5 undepleted bone marrow MNC
per plate were subsequently processed to clonal assays. Less
than 20% of bone marrow MNC were lost during the adherent
cell depletion.
Effect ofadherent cells on erythropoiesis
To test humoral factors from adherent cells inhibiting in vitro
erythropoiesis, we used the double layer system which con-
sisted of non-adherent cells in methylcellulose as an overlayer
and adherent cells in agar as an underlayer. According to the
procedure for adherent cell depletion stated above, 2 x 106/ml
bone marrow MNC from a CRF patient were cultured in I ml of
IMDM supplemented with 10% FCS for two hours in a 35-mm
Falcon dish (Falcon 3046, Becton Dickinson Labware, Oxnard,
California, USA) at 37°C in humidified air with 5% CO2. After
the removal of non-adherent cells by gentle pipetting, the
remaining adherent cells were covered with 0.5 ml of agar
(Difco Laboratories, Detroit, Michigan, USA) at a concentra-
tion of 0.5% in IMDM containing 30% FCS, 2 x l0— M 2-ME
and 500 mU/mI of Epo, which served as an underlayer for the
double-layer system. As a control, adherent cells from a normal
volunteer were cultured in the underlayer. Non-adherent cells
from a normal volunteer in methylcellulose were plated over the
agar as an overlayer for CFU-E assay.
Effect of indomethacin
Effects of indomethacin, an inhibitor of cyclo-oxygenase, on
colony growth of CFU-E, BFU-E and GM-CFC by bone
marrow MNC were studied to assess the effects of PG in the
development of anemia associated with CRF. Indomethacin
(Sigma) was dissolved in absolute ethanol and diluted in IMDM
at concentrations ranging from l0— to 10—6 M [29]. The
maximum ethanol concentration used for dissolving indometh-
acm did not affect colony growth.
Effect of uremic sera and PTH
Effects of uremic sera on colony growth of CFU-E, BFU-E
and GM-CFC by bone marrow MNC from a normal volunteer
were studied to investigate the relationship between the hu-
moral factors in uremic sera and erythropoiesis in patients with
CRF. Uremic sera were added to the methylcellulose mixture
for clonal assays at concentrations of 5, 10 and 15%. Human
synthetic N-terminal 1-34 P1'H (hs-PTH; Toyo Jozo Co. Ltd.
Tokyo, Japan) [30] was dissolved in IMDM and added to the
methylcellulose mixture for clonal assays at concentrations
ranging from 0 to 50 ng/ml.
Statistical analysis
The Student's t-test was employed for statistical analysis of
the data in the present study.
Results
Hematological and nephrological data
Characteristics of 37 patients and their clinical data were as
follows. The mean age was 51.9 years old (range: 30 to 70). The
mean hemoglobin concentration was 7.6 (range: 6.0 to 13.0),
serum creatinine and blood urea nitrogen were 12.5 4.0 mgldl
and 75.3 17.8 mg/dl, respectively. There was no correlation
observed between the hemoglobin level and age, levels of blood
urea nitrogen and creatinine, bone marrow nucleated cell
counts, proportion of erythroblasts in bone marrow or periods
on hemodialysis.
Responses of CFU-E to rEpo
To know whether erythroid progenitor cells are involved in
the development of CRF-associated anemia, responses of bone
marrow CFU-E to rEpo were studied in five patients undergo-
ing hemodialysis. Bone marrow MNC from three healthy nor-
mal volunteers were used as control. When bone marrow MNC
were cultured in the presence of rEpo, the number of CFU-E
colonies increased in a dose-dependent manner and reached to
the highest level at a concentration of 500 mU/ml of rEpo in
both normal and CRF groups (Fig. 1). However, the highest
level of CFU-E colonies was significantly lower in patients with
CRF than normal controls.
BFU-E colonies were significantly decreased in number in
CRF patients compared to normal controls (P < 0.01). In
contrast, the number of GM-CFC colonies did not differ from
those in normal controls (Fig. 2). The number of CFU-E and
BFU-E colonies did not correlate with age, hemoglobin con-
centration, levels of blood urea nitrogen and creatinine, and the
length of time on dialysis in these patients (data not shown).
Effect of bone marrow adherent cells on erythroid progenitor
cells
Next, we investigated a cell-mediated mechanism for the
suppression of in vitro growth of CFU-E in CRF patients.
Effects of bone marrow adherent cells were studied by using
clonal assays for CFU-E, BFU-E and GM-CFC. When adher-
ent cells were depleted from bone marrow MNC from CRF
patients, CFU-E colonies, but not BFU-E and GM-CFC colo-
nies, generally increased in number compared to those formed
by undepleted bone marrow MNC (Fig. 3). This effect was not
seen in normal controls (Table I).
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Fig. 1. Dose-response curves of CFU-E colony formation to rEpo in
patients with CRF. Bone marrow MNC were cultured for CFU-E
assays at concentrations ranging from 0 to 1,000 mU/mi of rEpo. in 3
normal controls (0, , U), each point and vertical bar represent the
mean SD in quadruplicated culture. In CRF patients (•). each point
and vertical bar represent the mean SD of the mean numbers of
CFU-E colonies in 5 patients.
Figure 4 shows that the number of CFU-E colonies by normal
bone marrow non-adherent cells was significantly suppressed
when the underlayer contained adherent cells from CRF pa-
tients (Fig. 4B) compared to those obtained when the under-
layer contained adherent cells from normal volunteers (Fig.
4A). On the other hand, the suppressive effect of adherent cells
on CFU-E colony formation was abolished when indomethacin
was added at a concentration of 106M to the double layer
system (Fig. 4C).
Effect of indomethacin on erythroid progenitor cells
Figure 5 indicates the effect of indomethacin on erythEoid
progenitor cells at concentrations of indomethacin ranging from
l0- M to l0_6 M. As shown in Figure 5A, the number of
CFU-E colonies formed by bone marrow MNC from a CRF
patient increased in a dose dependent manner, reaching to the
highest level at a concentration of 1O6 M. In contrast, addition
of indomethacin did not affect BFU-E colony formation. Figure
SB shows that indomethacin had no effect on CFU-E and
BFU-E colony formation by bone marrow non-adherent cells
from a CRF patient. Indomethacin had no effect on GM-CFC
colony formation at all concentrations studied (data not shown).
In normal control, indomethacin had no effect on CFU-E or
BFU-E colony formation (Fig. SC).
Table I summarizes data concerning the effect of adherent
cell depletion and addition of indomethacin on CFU-E colony
formation. Suppression of CFU-E was abolished by adherent
cell depletion from bone marrow MNC or addition of indometh-
acm to bone marrow MNC in patients with CRF.
Effect of uremic sera
As shown in Figure 6, uremic serum suppressed CFU-E
colony formation by normal bone marrow MNC in a dose
dependent manner. BFU-E and GM-CFC colony formation was
not significantly affected. Next, we examined the relationship
between the uremic serum, bone marrow adherent cells and
CFU-E colony formation. As shown in Figure 7, the suppres-
sive effect of uremic serum on CFU-E colony formation by
normal marrow MNC was significantly reversed by adherent
cell depletion or addition of indomethacin to inhibit the produc-
tion of endogenous PG.
Since uremic serum was suspected to contain some inhibitory
substances and PTH had been reported as a major uremic toxin,
the relationship between the serum concentration of PTH and
its inhibitory effect on CFU-E colony formation by normal bone
marrow MNC was studied. Uremic sera from seven patients
were added to the cultures at a final concentration of 10%.
Figure 8 shows that these uremic sera containing more than 8
ng/ml of PTH suppress CFU-E colony formation by normal
bone marrow MNC to 70% of control colonies.
Effect of hs-PTH
Next, we tested the inhibitory activity of hs-PTH, which had
been known to be the pure biological active PTH, against
erythroid progenitor cells to confirm the effect of PTH in sera.
As shown in Figure 9, hs-PTH suppressed CFU-E colony
formation by normal bone marrow MNC in a dose dependent
manner. This effect was also abolished by adherent cell deple-
tion and addition of indomethacin. On the other hand, hs-P'FH
failed to suppress BFU-E or GM-CFC colony formation by
bone marrow MNC (data not shown).
Discussion
The relationship between erythroid progenitor cells in the
bone marrow and the development of anemia in patients with
CRF has not been fully understood. The present study demon-
strates that both BFU-E and CFU-E colony formation by bone
marrow MNC in patients with CRF were significantly sup-
pressed at an optimal concentration of rEpo compared to
normal controls. Growth of myeloid progenitor cells (GM-CFC)
remained normal. Since the dose response pattern of CFU-E to
rEpo stimulation in CRF patients was similar to that in normal
controls, it is suggested that erythroid progenitor cells in CRF
patients can respond to Epo but their proliferation and differ-
entiation may be suppressed. In an animal model, CFU-E
derived colonies in the bone marrow were significantly de-
creased in rabbits with uremia which lasted for 35 days [31]. All
patients in the present study had been on hemodialysis for more
than two months (range: 2 to 156 months). It was also shown
that response patterns of bone marrow cells from CRF patients
to Epo were not different from those of normal controls when
erythropoiesis was evaluated by 59Fe incorporation into heme
[32). These observations indicate that despite the responsive-
ness of erythroid progenitor cells to Epo, their growth is
suppressed in a chronic uremic state.
Next, we studied the effect of bone marrow adherent cells on
erythropoiesis. When adherent cells were depleted from bone
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marrow MNC, CFU-E colony formation increased in patients
with CRF. The adherent cell depletion did not affect BFU-E or
GM-CFC colony formation. In contrast, adherent cells did not
influence on colony formation by CFU-E, BFU-E and GM-CFC
in normal controls. In the double layer co-culture system,
CFU-E colony formation by bone marrow non-adherent cells
from normal control was suppressed when bone marrow adher-
ent cells from CRF patients were co-cultured in the underlayer.
These data indicate that adherent cells from CRF patients
secreted some humoral factors suppressing CFU-E colony
formation. From the observation that the suppression was
abolished by the addition of indomethacin, a cyclo-oxygenase
inhibitor at a concentration of 10—6 M, it is indicated that the
CFU-E suppressive activity of bone marrow adherent cells
from CRF patients is mediated by PG. The effect of indometh-
acm was not demonstrated when adherent cells were depleted
before assaying CFU-E. Indomethacin did not affect CFU-E
and BFU-E colony formation by normal bone marrow MNC.
These findings are consistent with the results reported by
Snyder and Desforges [33]. These observations suggest that PG
may be a potent mediator when bone marrow adherent cells
from CRF patients suppress CFU-E colony formation. How-
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Fig. 2. The number of CFU-E, BFU-E, and
GM-CFC colonies in bone marrow MNC in
patients with CRF. Each point represents the
means in quadruplicate culture. Each long and
short horizontal bar represent the mean SD
of the mean value of colonies. * P <0.01.
Fig. 3. Effect of adherent cell depletion from
bone marrow MNC on CFU-E, BFU-E and
GM-CFC colony formation in patients with
CRF. Adherent cell depleted bone marrow
cells were cultured for assays of CFU-E,
BFU-E and GM-CFC in the presence of 500
mU/mI, 1,000 mU/mi, 1,000 mU/mi of rEpo,
respectively, Data were expressed as the
mean in quadruplicate culture. * P < 0.05,
** P <0.01.
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Table 1. Effects of adherent cell depletion and addition of
indomethacin on CFU-E colony formation
Case MNC
Non-
adherent
cells
MNC
+ IM
Non-
adherent
cells + IM
31. 100 1408b 1376b ND
32. 100 115.0 138.6" tj9,
33. 100 123.2 1456b 112.9
34. 100 1433b 150,0" 1379b
35. 100 125.6a l31.Oa 123.T
36. 100 132.Oa l36.8a l32.0
37. 100 l2l.4 l31,9a 119.7
Control
I. 100 99.6 93.3 88,6
2. 100 94.2 85.3 112.2
3. 100 90.1 93.1 92.5
4. 100 92.9 94.6 93.2
Bone marrow cells were obtained from 7 patients with CRF, and 4
normal healthy volunteers. Bone marrow MNC and non-adherent cells
were plated for CFU-E assay with or without indomethacin (IM) at a
concentration of 10. Data are expressed as percentages of colonies
formed by MNC. Four plates were used in each determination.
P < 0.05
bP < 0.01
Fig. 4. Effect of bone marrow adherent cells in CRF patients on
CFU-E colony formation by bone marrow non-adherent cells from
normal volunteers. Double-layer co-culture system was used to study
the effects of bone marrow adherent cells on CFU-E colony formation,
which consisted of bone marrow adherent cells from a CRF patient
overlaid with agar as underlayer and bone marrow non-adherent cells
from a normal volunteer in methylcellulose mixture for CFU-E assay as
overlayer (B). Indomethacin at a concentration of 10-6 M was added to
inhibit PG production by bone marrow cells (C). As the control,
adherent cells from a normal volunteer were served as underlayer (A).
Three identical experiments were performed. Each point and vertical
bar represent the means sn in quadruplicated cultures. * p < 0.01.
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Fig. 5. Effect of indomethacin on CFU-E and BFU-E colony formation
by bone marrow MNC from patients with CRF. Indomethacin at
concentrations ranging from l0- to 106 M was added to CFIJ-E (0)
and BFU-E (•) assay systems to inhibit PG production by bone marrow
cells. Target cells were bone marrow MNC from a patient with CRF
(A), non-adherent bone marrow cells from a patient (B), and bone
marrow MNC from a normal volunteer (C). Data were expressed as the
means SD in quadruplicated cultures. * P < 0.05, ** P < 0.01.
there have not been convincing data about the substance
suppressing erythropoiesis in uremic sera [17, 18]. In our
present study, uremic sera significantly suppressed CFU-E
colony formation by normal bone marrow MNC but not BFU-E
and GM-CFC. This suppression was mediated by the bone
marrow adherent cells and PG. Furthermore, the suppressive
effect was closely related with the concentrations of PTH in
sera. Our experiment using pure synthetic 1-34 N-terminal PTH
confirmed the assumption that high levels of PTH in the serum
may induce the secretion of PG from the bone marrow adherent
cells. Secondary hyperparathyroidism frequently occurs and
serum levels of PTH are often extremely high in patients with
CRF, and unexplained anemia is also encountered in patients
with primary hyperparathyroidism [13—16]. There have been
some reports that anemia improved after parathyroidectomy in
patients with CRF [16]. These observations suggest that PTH
may play some role in the development of CRF-associated
anemia at a level of CFU-E.
However, two problems remain to be studied in our results:
I) what mechanisms are operating in the suppression of BFU-E,
2) which derivative of PG will contribute to the suppression of
CFU-E. BFU-E colony formation in CRF patients was not
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ever, there may be another mechanism to suppress CFU-E,
because recovery of' CFU-E after adherent cell depletion or
addition of indomethacin was not complete.
Data concerning mechanisms involved in the suppression of
erythropoiesis in CRF patients have been controversial, and
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Concentration of uremic serum, %
Fig. 6. Effect of uremic sera on CFU-E, BFU-E and GM-CFC colony
formation by normal bone marrow MNC. Uremic sera at concentra-
tions of 5, 10, 15% were added to CFU-E (0), BFU-E (S) GM-CFC
(U) assay systems. Each point and vertical bar represent the mean SD
in quadruplicated culture. Data were expressed as percent of control
colonies. * P < 0.05, ** P < 0.01.
Concentration of uremic serum, %
Fig. 7. Effect of uremic serum on CFU-E colony formation by normal
bone marrow MNC. The effect of uremic serum on CFU-E colony
formation by bone marrow MNC (0), adherent cell depleted MNC (•)
and indomethacin added MNC (U) were studied. Each point and
vertical bar represent the mean SD in quadruplicated culture. Data
were expressed as percent of control colonies. * P <0.05, ** P <0.01.
Serum concentration of PTH, ng/mI
Fig. 8. Correlation between serum concentration of PTH and suppres-
sion of CFU-E colony formation by normal bone marrow MNC. The
effect of uremic sera from 7 patients with CRF which concentrations of
P'FH varified from normal range (0.2 to 0.5 ng/ml) to extremely high
level (30.8 nglml) on CFU-E colony formation by normal bone marrow
MNC was studied. All sera were added to the culture systems at a
concentration of 10%. Each data was expressed percent of control
colonies and represent the mean data in quadruplicate cultures.
Concentration of PTH, ng/m/
Fig. 9. Effect of hsPTH on CFU-E colony formation by normal bone
marrow MNC. hsPTH, which had been known to be the pure biological
active PTH, was added to culture system for CFU-E assays in concen-
trations ranging from 0 to 50 nglml. Target cells were three types, which
consisted of bone marrow MNC (0), adherent cell depleted MNC (•)
and 10-6 M of indomethacin added MNC (U). Each point and vertical
bar represent the mean data SD in quadruplicate cultures. Data were
expressed as percent of control colonies. ** P < 0.01.
measured the concentrations of PGF2a in a culture soup of bone
marrow adherent cells from patients with CRF and examined
whether anti-PGF2, polyclonal antibody could abolish PG-
mediated suppression or not. In our preliminary study, how-
ever, convincing data have not been obtained.
In conclusion, the present study indicates that the early and
late erythroid progenitor cells are suppressed in patients with
CRF though they can respond to Epo. Furthermore, suppres-
sion of CFU-E may be mediated by PG produced by bone
marrow adherent cells, and the production of PG is induced by
PTH. Therefore, it is suggested that PG-mediated suppression
of erythropoiesis may play an important role rather than the
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affected by the adherent cell depletion and the addition of
indomethacjn. One of possible explanations is that hemopoietic
growth factors in plasma from patients with aplastic anemia or
PHA-LCM other than rEpo might have overcome the PG-
mediated suppression.
There have been only few reports concerning PG-mediated
inhibition of erythropoiesis while many PG such as PGE1,
PGE2, PGA1, PGA2, PGB1, PGF1,,,trimethamine salt of PGF2,,
and PGI2 have been shown to stimulate erythropoiesis [34—37].
Chan, Saunders and Freedman reported that a free acid equiv-
alent of PGF2 suppressed CFU-E over a wide range of
concentrations [35]. Furthermore, an erythropoiesis inhibitory
factor was purified from human urine and was determined to be
PGF2 [37]. It is probable from these data that a CFU-E
suppressing factor observed in our study may be PGF2,. We
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inappropriate production of Epo in the development of anemia
in chronic renal failure.
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